Operator
Ladies and gentlemen, thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioStem Technologies First Quarter 2026 Earnings Call.
[Operator Instructions] Thank you. And I would now like to turn the conference over to Hannah Geoffrey, Investor Relations. You may begin.
Unknown Executive
Good afternoon, everyone, and thank you for joining our conference call to discuss BioStem’s First quarter 2026 financial results and corporate highlights. Leading the call today will be Jason Matuszewski, the company’s Chairman and Chief Executive Officer; Barry Hassett, the company’s Chief Commercial Officer; and Brandon Poe, the company’s Chief Financial Officer.
Before we begin, I’d like to remind everyone that our remarks may contain forward-looking statements based on management’s current expectations. These involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated. These risks are described in our filings with OTC Markets. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made. The company undertakes no obligation to update them unless required by law.
Finally, this call also includes references to non-GAAP financial measures. A reconciliation to comparable GAAP measures and related information can be found in our earnings press release posted on the Investor Relations section of BioStem’s website.
With that, I’d now like to turn
